Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Dimitrios P. Kontoyiannis(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Kayleigh Marx(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Sebastian Wurster(The University of Texas MD Anderson Cancer Center), David McCue(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Caitlin R. Rausch(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Kiran Naqvi(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Carol Bivins(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), Nathan P. Wiederhold(The University of Texas at San Antonio Health Science Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center)
Clinical Infectious Diseases
March 30, 2020
Cited by 78


Related Papers